Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
| Condition | Ulcerative Colitis, IBD |
|---|---|
| Phase | Phase 2 |
| Sponsor | AstraZeneca |
| Status | Terminated |
| Enrollment | 242 participants |
| Interventions | Brazikumab |
| Start date | Aug 7, 2018 |
| Completion date | Oct 23, 2023 |
| Results posted | Jun 23, 2026 |
Summary
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy
Clinical Remission
| Brazikumab 720 mg | 13 Participants |
|---|---|
| Brazikumab 1440 mg | 16 Participants |
| Brazikumab 2100 mg | 2 Participants |
| Vedolizumab | 0 Participants |
| Placebo | 4 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University